Actively Recruiting
Determinants of Chronic Inflammatory Skin Disease Trajectories
Led by University Hospital Schleswig-Holstein · Updated on 2025-07-22
1000
Participants Needed
1
Research Sites
35 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying chronic inflammatory skin diseases such as atopic dermatitis, psoriasis, and hidradenitis suppurativa, which show great variation in symptoms, severity, and treatment responses. The goal is to identify clinical and molecular factors that relate to disease subtypes and progression by closely following patients over a long period. This observational study aims to improve understanding of the natural course and variability of these conditions to help personalize patient care. Participants will be monitored through regular visits where clinical assessments and biological samples are collected. The study does not assign specific treatments but follows patients regardless of whether they use topical or systemic drugs. Evaluations occur at baseline, week 2, week 4, and then every three months for up to two years to capture changes in disease activity and molecular profiles over time. During the study, patients will undergo physician and patient assessments of disease activity, along with molecular testing from collected specimens. These measures are repeated regularly to track disease dynamics and flare-ups. The study includes safety considerations such as excluding recent use of certain immunosuppressive therapies. Participation can last up to two years, aiming to gather comprehensive data on disease progression and contributing factors.
CONDITIONS
Brief Title
Determinants of Chronic Inflammatory Skin Disease Trajectories
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Dermatologist-diagnosed inflammatory skin disease
- Ability to provide informed consent
You will not qualify if you...
- Unable to provide written informed consent
- Pregnant or breastfeeding women
- Concurrent participation in another clinical trial
- Use of systemic immunosuppressive therapy or phototherapy within the last 4 weeks
- Receipt of biologic therapy (e.g., dupilumab, tralokinumab) within the last 3 months
- Treatment of target skin areas with topical corticosteroids, calcineurin inhibitors, or emollients within 24 hours before sample collection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 years
Participants are observed over time with repeated clinical assessments and specimen collections to study the progression and molecular characteristics of their inflammatory skin disease.
Baseline, week 2, week 4, and every 3 months visits up to 2 years
Trial Site Locations
Total: 1 location
1
Department of Dermatology and Allergy, University Hospital Schleswig-Holstein
Kiel, Germany, 24105
Actively Recruiting
Research Team
S
Stephan Weidinger, MD
S
Stefanie Sievers
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here